Masahiro Fukuoka

发表

Personalized medicine and proteomics: lessons from non-small cell lung cancer.

György Marko-Varga, Atsushi Ogiwara, Toshihide Nishimura, 2007, Journal of proteome research.

Performance analysis of intermittently connected sensor networks

Kouji Hirata, Masahiro Muraguchi, Tomotaka Kimura, 2016, 2016 IEEE Region 10 Conference (TENCON).

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.

Masaaki Kawahara, Masahiro Fukuoka, Teruomi Miyazawa, 2003, Lung cancer.

Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.

Masahiro Fukuoka, M. Fukuoka, Y. Sakata, 2011, Japanese journal of clinical oncology.

Gefitinib in non-small cell lung cancer

Masahiro Fukuoka, Kenji Tamura, M. Fukuoka, 2005, Expert opinion on pharmacotherapy.

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Koichi Goto, Masahiro Fukuoka, Nobuyuki Yamamoto, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

Masahiro Fukuoka, Tomonori Hirashima, Kazuhiko Nakagawa, 2002, Lung cancer.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2010, Molecular Cancer Therapeutics.

Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine.

Masahiro Fukuoka, Andrew Emili, Douglas S Lee, 2007, The Canadian journal of cardiology.

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

Yusuke Nakamura, Tatsuhiko Tsunoda, Takashi Tsuruo, 2004, Human molecular genetics.

Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

Masaaki Kawahara, Masahiro Fukuoka, Yasumasa Nishimura, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Koichi Goto, Masahiro Fukuoka, Makoto Nishio, 2014, The Lancet. Oncology.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Masahiro Fukuoka, Yutaka Nishiwaki, Danny Rischin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2011 .

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Kenji Eguchi, Masahiro Tsuboi, Masahiro Fukuoka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib — a novel targeted approach to treating cancer

Masahiro Fukuoka, Roy S. Herbst, J. Baselga, 2004, Nature Reviews Cancer.

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Masahiro Fukuoka, Kenji Tamura, Junji Uchida, 2008, Molecular Cancer Therapeutics.